Canada Infectious Disease Drugs Market Analysis Report 2022 to 2030

Canada Infectious Disease Drugs Market Analysis

$ 3999

Canada Infectious Disease Drugs Market valued at $9.5 Bn in 2023, projected to reach $12.73 Bn by 2030 with a 4.27% CAGR. The market is driven by factors such as rising rates of infectious diseases, technological developments in medication development, and expanding healthcare infrastructure and awareness. The market is dominated by key players like Gilead Sciences, AbbVie Inc., GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, Pfizer Inc., and Sanofi.

ID: IN10CAPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Aneri Parekh

Buy Now

Canada Infectious Disease Drugs Market Executive Summary

Canada Infectious Disease Drugs Market valued at $9.5 Bn in 2023, projected to reach $12.73 Bn by 2030 with a 4.27% CAGR.

The Canadian market for infectious disease medications continues to evolve to meet the needs of both chronic illnesses and newly emerging infectious threats. The market includes a broad spectrum of pharmaceuticals that are intended to fight different infectious infections, such as antivirals, antibiotics, antifungals, and antiparasitic treatments. Furthermore, in the fight against infectious illnesses, alliances and cooperation amongst government organizations, academic institutions, and business leaders advance research and enhance treatment results.

The market for infectious disease drugs in Canada is resilient and expanding, driven by breakthroughs in pharmaceutical research, development, and distribution. Canada is a leader in the fight against new infections and long-standing public health issues because of its strong healthcare system and proactive response to infectious diseases. Market expansion is driven by factors such as rising infectious illness prevalence, supportive government measures, and increased awareness.

The global market for infectious disease drugs grew significantly, reaching $118.75 Bn in 2023. This expansion is due to a rise in the number of diagnoses as well as government initiatives to raise public awareness of the management of infectious illnesses. The market climate is changing, evident by the increase in generic competition. Moving forward, the key to long-term growth is to break down affordability obstacles and enhance access to treatment, particularly in developing nations. This will encourage further advancements and innovations in the sector.

Gilead Sciences is a significant player in the Canadian infectious disease pharmaceuticals industry, with a particular emphasis on HIV/ AIDS medications. HIV drugs produced by the business, including Descovy, Sunlenca, and Biktarvy, are well-liked and have a substantial market share in Canada. The business is also attempting to increase the accessibility of Biktarvy's low-dosage tablet form for the treatment of HIV in pediatric patients.

Canada infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Growing Incidence of Infectious Diseases: The need for medications to treat infectious diseases is fuelled by the growing frequency of infectious diseases.

Technological Developments: The creation of more effective and targeted drugs has increased the demand for infectious disease drugs in Canada.

Rising Awareness and Healthcare Infrastructure: Better access to infectious illness medications in Canada is made possible by advances in the healthcare infrastructure as well as growing awareness of the significance of early detection and treatment of infectious diseases.

Market Restraints:

Regulatory Obstacles: Companies aiming to bring novel therapies for infectious diseases to market may find considerable obstacles due to Canada's strict regulations approving new pharmaceuticals.

Pricing Pressures: Pharmaceutical companies face severe pricing pressures from Canada's public healthcare system, which may limit their ability to generate substantial earnings.

Competition from Generics: When branded pharmaceuticals' patents expire, generic equivalents frequently hit the market at a cheaper price, which lowers the original drug manufacturers' potential earnings.

Healthcare Policies and Regulatory Landscape

Health Canada's Health Products and Food Branch (HPFB) is the national agency in charge of overseeing and evaluating the efficacy, safety, and quality of therapeutic and diagnostic goods made available to Canadians. The drug product is subjected to a health technology assessment, following which a recommendation is issued regarding its eligibility for public funding. A pricing debate happens when a health technology assessment gives a product a positive recommendation. Health Canada applies strict scientific standards that necessitate comprehensive assessments of potential risks and benefits as well as solid clinical data. Producers may find this expensive and time-consuming, particularly when producing unique or specialized drugs.

Competitive Landscape

Key Players:

Gilead Sciences
AbbVie Inc.
GlaxoSmithKline plc
Merck & Co.
F. Hoffman-La Roche Ltd.
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG
Pfizer Inc.
Sanofi

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.